Free tool
FAERS Monitor: Simbrinza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204251 or its brand name (Simbrinza, Brimonidine Tartrate, Brinzolamide). Reports on generic versions are filed under their own applications.
Reports
4,182
Serious
1,782
43% of reports
Hospitalization
442
Death reported
150
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure382
- ocular hyperaemia366
- drug ineffective354
- eye irritation353
- vision blurred259
- eye pain237
- dizziness204
- hypersensitivity198
- intraocular pressure increased186
- visual impairment180
- fatigue174
- glaucoma157
- eye pruritus126
- headache120
- drug hypersensitivity117
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 15 |
| 2014 | 51 |
| 2015 | 156 |
| 2016 | 367 |
| 2017 | 507 |
| 2018 | 547 |
| 2019 | 487 |
| 2020 | 753 |
| 2021 | 333 |
| 2022 | 190 |
| 2023 | 193 |
| 2024 | 218 |
| 2025 | 213 |
| 2026 | 151 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,977 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 186 | 74.3 | 64.5 | 13,184 |
| glaucomaSignal | 157 | 41.3 | 35.4 | 6,095 |
| ocular hyperaemiaSignal | 366 | 39.1 | 35.4 | 13,469 |
| eye irritationSignal | 353 | 31.0 | 28.1 | 10,194 |
| treatment failureSignal | 382 | 23.3 | 21.2 | 8,123 |
| eye painSignal | 237 | 21.2 | 18.7 | 4,537 |
| eye pruritusSignal | 126 | 18.9 | 15.9 | 2,117 |
| vision blurredSignal | 259 | 9.5 | 8.4 | 1,971 |
| visual impairmentSignal | 180 | 7.3 | 6.3 | 979 |
| hypersensitivitySignal | 198 | 5.4 | 4.7 | 705 |
| drug hypersensitivitySignal | 117 | 3.0 | 2.5 | 160 |
| dizzinessSignal | 204 | 2.1 | 1.8 | 112 |
| drug ineffective | 354 | 1.4 | 1.2 | 34 |
| fatigue | 174 | 1.1 | 1.0 | 2 |
| headache | 120 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.